These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23162127)

  • 41. Specific and Cross-reactive Plasmablast Response in Humans after Primary and Secondary Immunization with Vi Capsular Polysaccharide Typhoid Vaccine.
    Pakkanen SH; Kantele JM; Rombo L; Kantele A
    Scand J Immunol; 2017 Oct; 86(4):207-215. PubMed ID: 28675263
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines.
    Tacket CO; Ferreccio C; Robbins JB; Tsai CM; Schulz D; Cadoz M; Goudeau A; Levine MM
    J Infect Dis; 1986 Aug; 154(2):342-5. PubMed ID: 2425009
    [No Abstract]   [Full Text] [Related]  

  • 43. Protection against Salmonella typhi infection in mice after immunization with outer membrane proteins isolated from Salmonella typhi 9,12,d, Vi.
    Isibasi A; Ortiz V; Vargas M; Paniagua J; González C; Moreno J; Kumate J
    Infect Immun; 1988 Nov; 56(11):2953-9. PubMed ID: 2844676
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH; Kantele JM; Herzog C; Kantele A
    Vaccine; 2014 Jan; 32(5):544-51. PubMed ID: 24342246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC; Klugman KP; Hunt S
    Vaccine; 2014 Apr; 32(20):2359-63. PubMed ID: 24630869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the immunogenicity and safety of two different brands of Salmonella typhi Vi capsular polysaccharide vaccine.
    Sabitha P; Prabha Adhikari MR; Chowdary A; Prabhu M; Soofi M; Shetty M; Kamath A; Lokaranjan SS; Bangera SS
    Indian J Med Sci; 2004 Apr; 58(4):141-9. PubMed ID: 15122049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Construction and characterization of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a.
    Cryz SJ; Fürer E; Baron LS; Noon KF; Rubin FA; Kopecko DJ
    Infect Immun; 1989 Dec; 57(12):3863-8. PubMed ID: 2807550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.
    Szu SC; Stone AL; Robbins JD; Schneerson R; Robbins JB
    J Exp Med; 1987 Nov; 166(5):1510-24. PubMed ID: 3681191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi.
    Rondini S; Micoli F; Lanzilao L; Pisoni I; Di Cioccio V; Saul AJ; Martin LB
    J Infect Dev Ctries; 2012 Nov; 6(11):763-73. PubMed ID: 23277501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Active protection of mice against Salmonella typhi by immunization with strain-specific porins.
    Isibasi A; Ortiz-Navarrete V; Paniagua J; Pelayo R; González CR; García JA; Kumate J
    Vaccine; 1992; 10(12):811-3. PubMed ID: 1333686
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.
    Micoli F; Rondini S; Pisoni I; Proietti D; Berti F; Costantino P; Rappuoli R; Szu S; Saul A; Martin LB
    Vaccine; 2011 Jan; 29(4):712-20. PubMed ID: 21115057
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi.
    Lu YJ; Zhang F; Sayeed S; Thompson CM; Szu S; Anderson PW; Malley R
    Vaccine; 2012 May; 30(23):3405-12. PubMed ID: 22465750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MyD88-dependent pro-inflammatory activity in Vi polysaccharide vaccine against typhoid promotes Ab switching to IgG.
    Garg R; Akhade AS; Yadav J; Qadri A
    Innate Immun; 2015 Oct; 21(7):778-83. PubMed ID: 26303218
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
    Klugman KP; Gilbertson IT; Koornhof HJ; Robbins JB; Schneerson R; Schulz D; Cadoz M; Armand J
    Lancet; 1987 Nov; 2(8569):1165-9. PubMed ID: 2890805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
    Kim YR; Yoo JH; Hur JK; Kang JH; Shin WS; Kang MW
    J Korean Med Sci; 1995 Oct; 10(5):314-7. PubMed ID: 8750055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.
    Honda-Okubo Y; Cartee RT; Thanawastien A; Seung Yang J; Killeen KP; Petrovsky N
    Vaccine; 2022 Jul; 40(32):4625-4634. PubMed ID: 35750538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune response variations to Salmonella enterica serovar Typhi recombinant porin proteins in mice.
    Toobak H; Rasooli I; Talei D; Jahangiri A; Owlia P; Darvish Alipour Astaneh S
    Biologicals; 2013 Jul; 41(4):224-30. PubMed ID: 23796754
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles.
    Meena J; Kumar R; Singh M; Ahmed A; Panda AK
    Eur J Pharm Biopharm; 2020 Jul; 152():270-281. PubMed ID: 32470636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Vi Capsular Polysaccharide of Salmonella Typhi Promotes Macrophage Phagocytosis by Binding the Human C-Type Lectin DC-SIGN.
    Zhang LF; Lepenies B; Nakamae S; Young BM; Santos RL; Raffatellu M; Cobb BA; Hiyoshi H; Bäumler AJ
    mBio; 2022 Dec; 13(6):e0273322. PubMed ID: 36286551
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen.
    Park SM; Ko HJ; Shim DH; Yang JY; Park YH; Curtiss R; Kweon MN
    J Immunol; 2008 Nov; 181(9):6447-55. PubMed ID: 18941235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.